Paradigm Biopharmaceuticals
(ASX:PAR) Share Price and News
About Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals was founded in 2011 to develop new treatments that would contribute to the management of unmet medical needs as a major international biopharmaceutical company.
Its flagship asset is Zilosul. Zilosul is a proprietary formulation of PPS (pentosan polysulfate sodium) which is a heterogeneous semi-synthetic drug manufactured from European beech-wood hemicelluloses. PPS works against osteoarthritis by blocking or inhibiting cartilage-degrading enzymes.
History of Paradigm Biopharmaceuticals
Formed in 2011, Paradigm Biopharmaceuticals had every interest in meeting very significant unmet medical needs and was molded into a major biopharmaceutical innovator. On its journey into the realm of drug development, it started off on the pathway of drug repurposing at which this company has been consolidating its growth.
The turning point arrived with the in-licensing of its lead product, Pentosan Polysulfate Sodium, initially proposed for the treatment of interstitial cystitis but with outstanding potential against osteoarthritis and other inflammatory disorders. It was this acquisition that provided the defining moment which launched the company into the mainstream arena in the biopharmaceutical sector.
The company worked its way through Phase I and Phase II, completing the latter in 2023. What was pleasing is not just that there was a reduction in pain, but that the reduction was sustained longer over time and that Zilosul resulted in an improvement in the cartilage thickness and volume.
Zilosul is not just another form of short-term pain relief, or even longer-term pain relief (although of course it does relieve pain), but it regenerates joint tissues in a way that existing treatments do not.
Future Outlook of Paradigm Biopharmaceuticals (ASX:PAR)
Paradigm Biopharmaceuticals is at an exciting and pivotal juncture in its development, currently at Phase 3 with Zilosul with the first enrolment in May 2025.
The company has told investors that while even though it is only 25% enrolled for the trial, it expects interim analysis in the middle of 2026 with primary endpoint analysis by the end of 2026.
Beyond the current PPS trial, the company is looking to broaden its osteoarthritis portfolio and in 2025 bought a company called Proteobioactives which is a company with an oral therapy (a combination of PPS) that could aid in earlier-stage OA and veterinary applications.
Is Paradigm Biopharmaceuticals (ASX:PAR) a Good Stock to Buy?
Yes, Paradigm Biopharmaceuticals does offer an opportunity for growth, with its innovative pipeline of drugs targeting unmet medical needs. This, however, requires successful clinical trials presently underway and finding a position in the competitive biopharmaceutical market. Although the strategic approach and progresses from the company look promising, investors must weigh risks from clinical trial outcomes and regulatory challenges against the potential for significant return. If so, with that, PAR could prove to be a good buy for investors with high risk tolerance who do not doubt the claimed therapeutic advancements.
Our Stock Analysis
There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps
There’s a Biotech Patent Cliff coming over the next decade! Investors aren’t giving this much attention, but we think they…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years
If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…
Ageing population stocks are set to derive significant long-term value
Ageing population stocks represent among the best long-term opportunities that exist for investors. Over the next 25 years, the world’s…
Frequently Asked Questions
Paradigm Biopharmaceuticals is a pharmaceutical drug development company. Primary expertise is in the re-purposing of existing drugs, and strategically, the focus of the business is on treatments for chronic pain and inflammatory conditions. Its lead product is Pentosan Polysulfate Sodium (PPS).